Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.3%
Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.3%
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) shot up 8.3% during mid-day trading on Wednesday . The company traded as high as $13.80 and last traded at $13.80. 5,581 shares were traded during mid-day trading, a decline of 99% from the average session volume of 846,361 shares. The stock had previously closed at $12.74.
賽特克生物科技股份有限公司(納斯達克代碼：CTKB-GET Rating)週三午盤大漲8.3%。該公司股價一度高達13.80美元，最新報13.80美元。午盤成交量為5,581股，較846,361股的平均日成交量下降99%。該股此前收盤價為12.74美元。
Analyst Ratings Changes
分析師評級發生變化
A number of brokerages have issued reports on CTKB. Piper Sandler boosted their target price on Cytek Biosciences from $12.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, August 17th. Morgan Stanley upped their price objective on Cytek Biosciences from $11.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Friday, August 12th. Finally, The Goldman Sachs Group upped their price objective on Cytek Biosciences from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th.
多家券商已經發布了關於CTKB的報告。派珀·桑德勒在8月17日(週三)的一份研究報告中將他們對Cytek Biosciences的目標價從12.00美元上調至16.00美元，並給出了該公司“增持”的評級。在8月12日星期五的一份研究報告中，摩根士丹利將賽特克生物科學公司的目標價從11.00美元上調至15.00美元，並給予該股“同等權重”的評級。最終，高盛夫婦在8月11日(星期四)的一份研究報告中將賽特克生物科學公司的目標價從15.00美元上調至17.00美元，並給予該股“買入”評級。
Cytek Biosciences Stock Up 10.1 %
Cytek Biosciences股價上漲10.1%
The firm has a fifty day moving average of $13.25 and a 200 day moving average of $11.38.
該公司的50日移動均線切入位為13.25美元，200日移動均線切入位為11.38美元。
Insider Activity at Cytek Biosciences
賽特克生物科學公司的內部活動
In other Cytek Biosciences news, CEO Wenbin Jiang sold 20,000 shares of the company's stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.09, for a total value of $301,800.00. Following the completion of the transaction, the chief executive officer now owns 7,841,541 shares in the company, valued at $118,328,853.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Patrik Jeanmonod sold 3,500 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $12.80, for a total transaction of $44,800.00. Following the completion of the sale, the chief financial officer now owns 94,994 shares in the company, valued at $1,215,923.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $15.09, for a total transaction of $301,800.00. Following the sale, the chief executive officer now owns 7,841,541 shares of the company's stock, valued at approximately $118,328,853.69. The disclosure for this sale can be found here. Insiders have sold 127,000 shares of company stock valued at $1,632,675 over the last quarter. 15.90% of the stock is owned by insiders.
在Cytek Biosciences的其他消息中，首席執行官蔣文斌在8月8日星期一的一筆交易中出售了20,000股公司股票。這些股票的平均價格為15.09美元，總價值為301,800.00美元。交易完成後，首席執行官現在擁有該公司7841股，價值118,328,853.69美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過此超鏈接。在其他新聞方面，首席財務官Patrik Jeanmonod在8月1日星期一的交易中出售了3500股該公司股票。這些股票以12.80美元的平均價格出售，總成交額為44,800.00美元。出售完成後，首席財務官現在擁有該公司94,994股，價值1,215,923.20美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過這個環節。此外，首席執行官蔣文斌在8月8日星期一的交易中出售了2萬股該股。該股以15.09美元的平均價格出售，總成交金額為301,800.00美元。出售後，首席執行官現在擁有7841,541股公司股票，價值約118,328,853.69美元。關於這次銷售的披露可以找到這裏。在上個季度，內部人士已經出售了12.7萬股公司股票，價值1,632,675美元。15.90%的股份由內部人士持有。
Institutional Investors Weigh In On Cytek Biosciences
機構投資者看好賽特克生物科學公司
Several hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY boosted its stake in shares of Cytek Biosciences by 31.5% during the first quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock worth $69,000 after buying an additional 1,536 shares during the period. Royal Bank of Canada lifted its position in Cytek Biosciences by 64.1% in the first quarter. Royal Bank of Canada now owns 5,995 shares of the company's stock valued at $65,000 after purchasing an additional 2,341 shares during the period. FMR LLC lifted its position in Cytek Biosciences by 0.5% in the second quarter. FMR LLC now owns 520,845 shares of the company's stock valued at $5,589,000 after purchasing an additional 2,616 shares during the period. American International Group Inc. lifted its position in Cytek Biosciences by 10.3% in the second quarter. American International Group Inc. now owns 53,444 shares of the company's stock valued at $573,000 after purchasing an additional 5,003 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its position in Cytek Biosciences by 514.7% in the first quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company's stock valued at $82,000 after purchasing an additional 6,336 shares during the period. Institutional investors and hedge funds own 43.54% of the company's stock.
幾家對衝基金最近改變了他們在該業務中的頭寸。紐約大都會人壽保險公司在第一季度將其在Cytek Biosciences的持股增加了31.5%。紐約大都會人壽保險公司在此期間又購買了1,536股，現在擁有6,415股該公司股票，價值69,000美元。加拿大皇家銀行在第一季度將其在賽特克生物科學的頭寸提升了64.1%。加拿大皇家銀行在此期間又購買了2341股，現在持有5995股該公司股票，價值65,000美元。FMR LLC在第二季度將其在Cytek Biosciences的頭寸提高了0.5%。FMR LLC現在擁有該公司520,845股股票，價值5,589,000美元，在此期間又購買了2,616股。美國國際集團(American International Group Inc.)在第二季度將其在Cytek Biosciences的頭寸提高了10.3%。在此期間，美國國際集團又購買了5,003股，目前持有53,444股該公司股票，價值573,000美元。最後，ameritas Investment Partners Inc.在第一季度將其在賽特克生物科學公司的持倉提高了514.7%。Ameritas Investment Partners Inc.在此期間又購買了6,336股，目前持有該公司7,567股股票，價值82,000美元。機構投資者和對衝基金持有該公司43.54%的股票。
Cytek Biosciences Company Profile
賽特克生物科學公司簡介
(Get Rating)
(獲取評級)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家細胞分析解決方案公司，提供細胞分析工具，促進生物醫學研究和臨牀應用的科學進步。它提供極光和北極光系統，這是一種光譜流動細胞儀，通過利用來自多個激光的熒光信號來區分單個細胞上的熒光標記來提供細胞分析；以及極光細胞分選系統，它利用全光譜圖譜技術進一步拓寬了細胞分析的潛在應用。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- 免費獲取StockNews.com關於Cytek生物科學的研究報告(CTKB)
- 聯合天然食品能同時對抗通脹和美聯儲嗎？
- 馬倫汽車已做好準備投入使用
- 餅乾桶：可口的款待還是壞蘋果？
- 防禦性股票應對動盪的市場
- SunPower準備推動三位數的收益增長
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cytek Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。